Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy

A double-blind crossover trial was performed to assess the effect of metoprolol in 10 patients (mean age 55 years) with severe dilated cardiomyopathy. All patients clinically had idiopathic dilated cardiomyopathy; however, at coronary angiography, four had occult coronary disease. All were in New York Heart Association functional class III with a left ventricular ejection fraction less than 35% as assessed by rest radionuclide ventriculography. Studies were performed before treatment, after 4 weeks of metoprolol therapy and after 4 weeks of placebo administration. Erect bicycle sprint exercise was used to determine maximal work load. Hemodynamic variables and radionuclide left ventricular ejection fraction were recorded at rest and during graded supine bicycle exercise. Cardiac medications were unchanged throughout the trial. The mean (+/- standard error of the mean) dose of metoprolol was 130 +/- 13 mg/day. Metoprolol did not change symptoms, chest X-ray findings or exercise tolerance (baseline 700 +/- 73, placebo 690 +/- 85, metoprolol 710 +/- 81 kilopond-meters [kpm]/min). Metoprolol produced a significant decrease in heart rate at rest and during exercise (p less than 0.001). Mean blood pressure and left ventricular filling pressure did not differ significantly in the baseline, placebo and metoprolol studies. There was a slight, but significant (p less than 0.05) decrease in cardiac index with metoprolol compared with placebo and baseline studies. The small, but significant increase in left ventricular ejection fraction from baseline to the metoprolol and placebo studies (p less than 0.001) was considered a result of spontaneous improvement rather than of therapy. No significant differences were found between the patients with and without coronary disease.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. L. Mann and M. R. Bristow Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond Circulation, May 31, 2005; 111(21): 2837 - 2849. [Full Text] [PDF]

				J. M. Foody, M. H. Farrell, and H. M. Krumholz {beta}-Blocker Therapy in Heart Failure: Scientific Review JAMA, February 20, 2002; 287(7): 883 - 889. [Abstract] [Full Text] [PDF]

				H. Persson, K. Andreasson, T. Kahan, S. V. Eriksson, B. Tidgren, P. Hjemdahl, C. Hall, and L. Erhardt Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists Eur J Heart Fail, January 1, 2002; 4(1): 73 - 82. [Abstract] [Full Text] [PDF]

				L. Gullestad, C. Manhenke, T. Aarsland, R. Skardal, H. Fagertun, J. Wikstrand, and J. Kjekshus Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure -- a substudy to the MERIT-HF trial Eur J Heart Fail, August 1, 2001; 3(4): 463 - 468. [Abstract] [Full Text] [PDF]

				S. Genth-Zotz, R. J. Zotz, M. Sigmund, P. Hanrath, D. Hartmann, M. Bohm, F. Waagstein, N. Treese, J. Meyer, and H. Darius MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing Eur J Heart Fail, June 1, 2000; 2(2): 175 - 181. [Abstract] [Full Text] [PDF]

				Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy : The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study Circulation, February 1, 2000; 101(4): 378 - 384. [Abstract] [Full Text] [PDF]

				M. L. Kukin, M. M. Mannino, R. S. Freudenberger, J. Kalman, C. Buchholz-Varley, and O. Ocampo Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure J. Am. Coll. Cardiol., January 1, 2000; 35(1): 45 - 50. [Abstract] [Full Text] [PDF]

				J. K. Gwathmey, C. S. Kim, R. J. Hajjar, F. Khan, T. G. DiSalvo, A. Matsumori, and M. R. Bristow Cellular and molecular remodeling in a heart failure model treated with the beta -blocker carteolol Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1678 - H1690. [Abstract] [Full Text] [PDF]

				M. Packer, W. S. Colucci, J. D. Sackner-Bernstein, C.-s. Liang, D. A. Goldscher, I. Freeman, M. L. Kukin, V. Kinhal, J. E. Udelson, M. Klapholz, et al. Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure: The PRECISE Trial Circulation, December 1, 1996; 94(11): 2793 - 2799. [Abstract] [Full Text]

				E. J. Eichhorn and M. R. Bristow Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart: A New Era in the Treatment of Heart Failure Circulation, November 1, 1996; 94(9): 2285 - 2296. [Abstract] [Full Text]

				J. D. Sackner-Bernstein and D. M. Mancini Rationale for Treatment of Patients With Chronic Heart Failure With Adrenergic Blockade JAMA, November 8, 1995; 274(18): 1462 - 1467. [Abstract] [PDF]

				COMMITTEE MEMBERS, J. F. WILLIAMS Jr, M. R. BRISTOW, M. B. FOWLER, G. S. FRANCIS, A. GARSON Jr, B. J. GERSH, D. F. HAMMER, M. A. HLATKY, C. V. LEIER, et al. Guidelines for the Evaluation and Management of Heart Failure : Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) Circulation, November 1, 1995; 92(9): 2764 - 2784. [Full Text]

				A. M. Feldman Can We Alter Survival in Patients With Congestive Heart Failure? JAMA, April 8, 1992; 267(14): 1956 - 1961. [Abstract] [PDF]

				M. Packer Clinical Trials in Congestive Heart Failure: Why Do Studies Report Conflicting Results? Ann Intern Med, July 1, 1988; 109(1): 3 - 5. [Abstract] [PDF]

				P. R. Marantz, M. H. Alderman, and J. N. Tobin Diagnostic Heterogeneity in Clinical Trials for Congestive Heart Failure Ann Intern Med, July 1, 1988; 109(1): 55 - 61. [Abstract] [PDF]